<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480593</url>
  </required_header>
  <id_info>
    <org_study_id>31099320.6.0000.0048</org_study_id>
    <nct_id>NCT04480593</nct_id>
  </id_info>
  <brief_title>The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.</brief_title>
  <acronym>Bee-Covid</acronym>
  <official_title>The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D'Or Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>D'Or Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic is of grave concern due its impact on human health and on the economy.
      Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory,
      immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection
      mechanism are potential targets for propolis compounds. Propolis components have inhibitory
      effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has
      been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the
      impact of using Brazilian green propolis extract against the deleterious effects of the new
      coronavirus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>three parallel groups randomly assigned</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The individual who evaluates the results of interest to the study will not have access to the study steps before the analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite clinical outcome with oxygen therapy dependency time or hospitalization time</measure>
    <time_frame>1-28 days</time_frame>
    <description>Composite clinical outcome with oxygen therapy dependency time (in days) or hospitalization time (in days) after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events during the use of propolis</measure>
    <time_frame>1-28 days</time_frame>
    <description>We will evaluate the presence or absence of symptoms related to the use of propolis through a questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and severity of acute kidney injury during the study</measure>
    <time_frame>1-28 days</time_frame>
    <description>Assess the degree of acute kidney injury according to KDIGO (through serum creatinine or urine output).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy.</measure>
    <time_frame>1-28 days</time_frame>
    <description>Assess need or not for renal replacement therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of need for vasopressor use</measure>
    <time_frame>1-28 days</time_frame>
    <description>Describe the time needed for vasopressors in days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intensive care unit (ICU)</measure>
    <time_frame>1-28 days</time_frame>
    <description>Assess length of stay in the ICU after randomization in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) readmission</measure>
    <time_frame>1-28 days</time_frame>
    <description>Rate of readmission to the ICU after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive oxygenation time</measure>
    <time_frame>1-28 days</time_frame>
    <description>Assess the need for mechanical ventilation in days after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of plasma c-reactive protein</measure>
    <time_frame>1-7 days</time_frame>
    <description>Evaluate the variation in serum levels of c-reactive protein over the 7 days after randomization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPP-AF 400mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green propolis extract (EPP-AF) at a dose of 400mg / day in addition to the standard treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPP-AF 800mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green propolis extract (EPP-AF) at a dose of 800mg / day in addition to the standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brazilian Green Propolis Extract (EPP-AF)</intervention_name>
    <description>Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.</description>
    <arm_group_label>EPP-AF 400mg/day</arm_group_label>
    <arm_group_label>EPP-AF 800mg/day</arm_group_label>
    <other_name>Standard care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients;

          -  Positive RT-PCR for SARS-CoV-2;

          -  18 Years and older.

        Exclusion Criteria:

          -  Pregnant women;

          -  People with active cancer;

          -  Patients undergoing transplantation of solid organs or bone marrow or who use
             immunosuppressive medications;

          -  HIV carriers;

          -  Allergy to propolis or any of its components;

          -  Bacterial infection at randomization;

          -  Sepsis or septic shock before randomization;

          -  Patients unable to use medication orally or via nasoenteral tube;

          -  Patients with severe chronic liver disease (Child B or C);

          -  Patients with advanced heart failure;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Silveira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>D'Or Institute for Research and Education (IDOR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sao Rafael</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>41820340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Hori JI, Zamboni DS, Carr√£o DB, Goldman GH, Berretta AA. The Inhibition of Inflammasome by Brazilian Propolis (EPP-AF). Evid Based Complement Alternat Med. 2013;2013:418508. doi: 10.1155/2013/418508. Epub 2013 Apr 16.</citation>
    <PMID>23690844</PMID>
  </reference>
  <results_reference>
    <citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019. Review.</citation>
    <PMID>32282022</PMID>
  </results_reference>
  <results_reference>
    <citation>Maruta H, He H. PAK1-blockers: Potential Therapeutics against COVID-19. Med Drug Discov. 2020 Jun;6:100039. doi: 10.1016/j.medidd.2020.100039. Epub 2020 Apr 19. Review.</citation>
    <PMID>32313880</PMID>
  </results_reference>
  <results_reference>
    <citation>Serkedjieva J, Manolova N, Bankova V. Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids). J Nat Prod. 1992 Mar;55(3):294-302.</citation>
    <PMID>1593279</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr√ºger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, M√ºller MA, Drosten C, P√∂hlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </results_reference>
  <results_reference>
    <citation>Machado JL, Assun√ß√£o AK, da Silva MC, Dos Reis AS, Costa GC, Arruda Dde S, Rocha BA, Vaz MM, Paes AM, Guerra RN, Berretta AA, do Nascimento FR. Brazilian green propolis: anti-inflammatory property by an immunomodulatory activity. Evid Based Complement Alternat Med. 2012;2012:157652. doi: 10.1155/2012/157652. Epub 2012 Dec 19.</citation>
    <PMID>23320022</PMID>
  </results_reference>
  <results_reference>
    <citation>Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res. 2020 Jul 15;284:197989. doi: 10.1016/j.virusres.2020.197989. Epub 2020 Apr 30. Review.</citation>
    <PMID>32360300</PMID>
  </results_reference>
  <results_reference>
    <citation>Silveira MAD, Teles F, Berretta AA, Sanches TR, Rodrigues CE, Seguro AC, Andrade L. Effects of Brazilian green propolis on proteinuria and renal function in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial. BMC Nephrol. 2019 Apr 25;20(1):140. doi: 10.1186/s12882-019-1337-7.</citation>
    <PMID>31023272</PMID>
  </results_reference>
  <results_reference>
    <citation>Cusinato DAC, Martinez EZ, Cintra MTC, Filgueira GCO, Berretta AA, Lanchote VL, Coelho EB. Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF¬Æ) using an in vivo cocktail approach. J Ethnopharmacol. 2019 Dec 5;245:112174. doi: 10.1016/j.jep.2019.112174. Epub 2019 Aug 20.</citation>
    <PMID>31442620</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 12, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>D'Or Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Marcelo Silveira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Propolis</keyword>
  <keyword>Covid19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Anti-inflammatory</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propolis</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

